How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,738 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Psoriasis and dementia: a systematic review

Psoriasis and dementia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

182. Role of fish oil and its ingredients in the treatment of psoriasis: a systematic review and meta-analysis

Role of fish oil and its ingredients in the treatment of psoriasis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

183. Effectiveness comparisons of acupuncture for psoriasis: a network meta-analysis

Effectiveness comparisons of acupuncture for psoriasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

184. Mortality in psoriasis and psoriatic arthritis: a systematic review and meta-analysis

Mortality in psoriasis and psoriatic arthritis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

185. Effectiveness comparisons of Traditional Chinese medicine for psoriasis: a network meta-analysis

Effectiveness comparisons of Traditional Chinese medicine for psoriasis: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

186. Could acitetrin treatment modify immunological parameters in psoriasis patients? A systematic review

Could acitetrin treatment modify immunological parameters in psoriasis patients? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

187. Association between psoriasis and migraine

Association between psoriasis and migraine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

188. The risk of cancer in patients with psoriasis: a systematic review and meta-analysis

The risk of cancer in patients with psoriasis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

189. Do Psoriasis patients suffer from worse periodontal status-a meta-analysis

Do Psoriasis patients suffer from worse periodontal status-a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

190. Dimethyl fumarate for treating moderate to severe plaque psoriasis

Dimethyl fumarate for treating moderate to severe plaque psoriasis Dimeth Dimethyl fumar yl fumarate for treating moder ate for treating moderate ate to se to sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta475 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 The technology 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

191. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people Adalimumab, etanercept and Adalimumab, etanercept and ustekinumab for treating plaque psoriasis ustekinumab for treating plaque psoriasis in children and y in children and young people oung people T echnology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

192. Ixekizumab for treating moderate to severe plaque psoriasis

Ixekizumab for treating moderate to severe plaque psoriasis Ix Ixekizumab for treating moder ekizumab for treating moderate to ate to se sev vere plaque psoriasis ere plaque psoriasis T echnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ixekizumab for treating moderate to severe plaque psoriasis (TA442) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents 1 Recommendations 4 2 The technology 5 3 Evidence 6 4

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

193. Efficacy and safety of Tildrakizumab for treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis

Efficacy and safety of Tildrakizumab for treatment of moderate to severe plaque psoriasis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

194. Efficacy and safety of the treatments for nail psoriasis. Systematic review and meta-analysis

Efficacy and safety of the treatments for nail psoriasis. Systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

195. Treatment of erythrodermic psoriasis with biologics: a systematic review

Treatment of erythrodermic psoriasis with biologics: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

196. The impact of smoking in the development of psoriasis and psoriatic arthritis: a systematic review and meta-analysis

The impact of smoking in the development of psoriasis and psoriatic arthritis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

197. Psoriasis and venous thromboembolism: systematic review of the literature

Psoriasis and venous thromboembolism: systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

198. The association of serum uric acid levels in psoriasis patients: a systematic review and network meta-analysis

The association of serum uric acid levels in psoriasis patients: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

199. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. (PubMed)

Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. Although 40% of psoriasis patients reported skin pain, this symptom is often underestimated. A new formula of calcipotriol plus betamethasone dipropionate (Cal/BD) has been recently approved for psoriasis treatment. Therefore, we aimed to evaluate the efficacy of Cal/BD aerosol foam on skin pain of patients with plaque psoriasis.A real-life 4-week prospective, open study (...) on Cal/BD aerosol foam (not compared to vehicle or emollient cream) was performed in adult psoriasis patients attending three Dermatology units located in Campania region, Italy, between March and October 2018. Inclusion criteria were a history of skin pain over the last week and psoriatic involvement of the palmar area. Before (t0) and after a course of once daily application of Cal/BD aerosol foam for 4 weeks (t1), the following items were evaluated: Psoriasis Area and Severity Index (PASI

2019 Journal of the European Academy of Dermatology and Venereology

200. General health status in psoriasis patients, as assessed by the SF-12 questionnaire, is poorly associated with PASI. (PubMed)

General health status in psoriasis patients, as assessed by the SF-12 questionnaire, is poorly associated with PASI. An important issue in medicine is how to measure the clinical severity of a disease. In psoriasis this is traditionally assessed using the Psoriasis Area and Severity Assessment (PASI). However, it is a concern that this measure does not really capture the burden that the disease has on patients. The aim of this observational study was to assess, in patients with psoriasis

2019 Journal of the European Academy of Dermatology and Venereology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>